c-Kit Mutation Detection Kit

Available Products

Product Name/Description
No. of Reactions*
Product Code
c-Kit Mutation Detection Kit for Real-Time PCR

*Includes all controls.


c-Kit Mutations in Melanoma

KIT mutations are found in approximately five to 30 percent of acral and mucosal melanomas and melanomas arising on chronically sun-damaged skin. Mutations occur primarily in exon 11 and secondarily in exons 13, 17, and 18. The overall response rate to imatinib in KIT-mutated melanoma is 16 to 23 percent, demonstrating the value of KIT-mutation testing in melanoma patients. [1][2][3]

The c-Kit Mutation Detection Kit detects the following mutations:

Mutation COSMIC ID
EX11_ p.V559D COSM1252
EX11_p.V559G COSM1253
EX11_p.V560D COSM1257
EX11_W557R COSM1216
EX17_p.D816H COSM1311
EX17_p.D816V COSM1314
EX11_p.L576P COSM1290
EX13_p.K642E COSM1304
EX9_p.Y503_F504insAY COSM12444
EX11_p.W557_E561del COSM18890
EX11_p.W557_K558del COSM12449
EX11_p.W557_V559>C COSM1233
EX11_p.W557_V559>F COSM1226
EX17_p.N822Y COSM19109
EX17_p.K818R COSM1315
EX17_p.N822H COSM1318
EX11_p.V559A COSM1255
EX11_p.W557G COSM1221
EX17_p.D820G COSM1316
EX17_p.D820Y COSM12710
EX17_p.N822K COSM1322


Testing Procedure and Analysis

EntroGen’s c-Kit Mutation Detection Kit is a polymerase chain reaction (PCR)-based assay that uses allele-specific primers to identify the presence of somatic mutations in c-KIT genes. The testing procedure involves three (3) simple steps:

  • Isolation of DNA from tumor biopsies, paraffin-embedded sections (FFPE), or fine needle aspirates (FNA)
  • Amplification of regions of the c-KIT genes using allele-specific primers
  • Analysis of the captured amplification data.

This test can be completed in approximately 2 hours from isolation of DNA to test result.


Equipment and Materials

EntroGen’s c-Kit Mutation Detection Kit requires a real-time PCR instrument capable of detecting FAM, VIC, ROX and CY5 fluorescent probes.

This test includes reagents required for the PCR amplification/detection, as well as validated reaction controls. Columns and reagents for DNA isolation are not included.


Intended Use


EntroGen’s Thyroid Cancer Mutation Panel is provided for research use only (RUO). Not for use in diagnostic procedures.


EntroGen’s Thyroid Cancer Mutation Panel is available for research (RUO) and diagnostic (CE-IVD) purposes.


[1] Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31(26):3182-3190.

[2] Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327-2334.

[3] Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29(21):2904-2909.

More Product Info